Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100402029 | 10040202 | 9 | F | 20131214 | 20140925 | 20140327 | 20140930 | EXP | BR-009507513-1401BRA008286 | MERCK | 82.00 | YR | F | Y | 56.90000 | KG | 20140930 | N | MD | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100402029 | 10040202 | 1 | PS | BLINDED ODANACATIB | UNSPECIFIED INGREDIENT | 1 | ORAL | UNK | D | 0 | TABLET | ||||||||
| 100402029 | 10040202 | 2 | SS | BLINDED ODANACATIB | UNSPECIFIED INGREDIENT | 1 | ORAL | UNK | D | 0 | TABLET | ||||||||
| 100402029 | 10040202 | 3 | SS | VITAMIN D3 | CHOLECALCIFEROL | 1 | ORAL | 5600 IU QW | D | 0 | TABLET | /wk | |||||||
| 100402029 | 10040202 | 4 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | ORAL | 40 MG, QD | 280 | MG | D | 70017 | 40 | MG | TABLET | QD | |||
| 100402029 | 10040202 | 5 | SS | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | ORAL | 100 MG, QD | 700 | MG | D | 0 | 100 | MG | TABLET | QD | |||
| 100402029 | 10040202 | 6 | C | LEVOTHYROXINE SODIUM. | LEVOTHYROXINE SODIUM | 1 | ORAL | 50 MICROGRAM, QD | U | 0 | 50 | UG | TABLET | QD | |||||
| 100402029 | 10040202 | 7 | C | ENALAPRIL MALEATE. | ENALAPRIL MALEATE | 1 | ORAL | 5 MG, BID | 10800 | MG | U | 0 | 5 | MG | TABLET | BID | |||
| 100402029 | 10040202 | 8 | C | LACRIFILM | 2 | OPHTHALMIC | 1 DROPS, TID | U | 0 | 1 | GTT | EYE DROPS, SOLUTION | TID | ||||||
| 100402029 | 10040202 | 9 | C | CALCIUM CARBONATE. | CALCIUM CARBONATE | 1 | ORAL | 500 MG, QD | 232000 | MG | U | 0 | 500 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 100402029 | 10040202 | 1 | Osteoporosis postmenopausal |
| 100402029 | 10040202 | 3 | Osteoporosis |
| 100402029 | 10040202 | 4 | Cardiac failure congestive |
| 100402029 | 10040202 | 5 | Cardiac failure congestive |
| 100402029 | 10040202 | 6 | Hypothyroidism |
| 100402029 | 10040202 | 7 | Hypertension |
| 100402029 | 10040202 | 8 | Cataract operation |
| 100402029 | 10040202 | 9 | Osteoporosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 100402029 | 10040202 | HO |
| 100402029 | 10040202 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 100402029 | 10040202 | Acute myocardial infarction | |
| 100402029 | 10040202 | Cardiac failure | |
| 100402029 | 10040202 | Hyperkalaemia | |
| 100402029 | 10040202 | Ventricular fibrillation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 100402029 | 10040202 | 1 | 20090905 | 20130810 | 0 | |
| 100402029 | 10040202 | 2 | 20130824 | 20131207 | 0 | |
| 100402029 | 10040202 | 3 | 20090825 | 20131214 | 0 | |
| 100402029 | 10040202 | 4 | 20131220 | 20140109 | 0 | |
| 100402029 | 10040202 | 5 | 20131220 | 20140109 | 0 | |
| 100402029 | 10040202 | 6 | 20100220 | 0 | ||
| 100402029 | 10040202 | 7 | 20110105 | 20131219 | 0 | |
| 100402029 | 10040202 | 8 | 20110429 | 0 | ||
| 100402029 | 10040202 | 9 | 20120907 | 20131214 | 0 |